RT Book, Section
A1 Cardarella, Stephanie
A1 Johnson, Bruce E.
A2 Sugarbaker, David J.
A2 Bueno, Raphael
A2 Colson, Yolonda L.
A2 Jaklitsch, Michael T.
A2 Krasna, Mark J.
A2 Mentzer, Steven J.
A2 Williams, Marcia
A2 Adams, Ann
SR Print(0)
ID 1105843323
T1 Adjuvant and Neoadjuvant Chemotherapy
T2 Adult Chest Surgery, 2e
YR 2015
FD 2015
PB McGraw-Hill Education
PP New York, NY
SN 978-0-07-178189-3
LK accesssurgery.mhmedical.com/content.aspx?aid=1105843323
RD 2024/09/17
AB The  most  effective  treatment  for  early-stage  (I–IIIA)  non–small-cell  lung  cancer  (NSCLC)  is  surgical  resection.  Despite  optimal  surgical  techniques  employed  for  the  resections,  a  substantial  percentage  of  patients  with  stage  I–IIIA  NSCLC  subsequently  relapse  and  die  from  their  lung  cancer.1  Studies  that  suggested  adjuvant  chemotherapy  could  prolong  survival  for  some  patients  with  early-stage  lung  cancer  began  to  emerge.  A  number  of  trials  have  since  documented  that  the  use  of  chemotherapy  in  both  the  preoperative  (neoadjuvant)  and  postoperative  (adjuvant)  settings  can  prolong  survival.  This  chapter  summarizes  the  evidence  showing  the  benefit  from  adjuvant  and  neoadjuvant  therapy  for  specific  subgroups  of  patients  with  early-stage  NSCLC.